<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4093</id>
  <title>T3D4039</title>
  <common-name>Gonyautoxin II</common-name>
  <description>Gonyautoxin II is a neurotoxin that is a sodium channel blocker.</description>
  <cas>60508-89-6</cas>
  <pubchem-id>11593018</pubchem-id>
  <chemical-formula>C10H17N7O8S</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point></melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure nil="true"/>
  <target nil="true"/>
  <mechanism-of-toxicity>The gonyautoxin toxicity is caused by the reversibly binding to its receptor site on the voltage-gated sodium channel on excitable cells, thus blocking the influx of Na+ ions and preventing nerve and muscle cells from producing action potentials, therefore, blocking neuronal transmission, which results in a temporary paralysis of muscles. Gonyautoxin paralyzes the injected sphincter reducing anal tone, leaving the other muscles unaffected. The paretic effect lasts for more than one week. Its effect is dose-dependent and the binding to its receptor site is only regulated by affinity.(A3261)</mechanism-of-toxicity>
  <metabolism nil="true"/>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Gonyautoxin II is a neurotoxin that is a sodium channel blocker.</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms nil="true"/>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T04:54:37Z</created-at>
  <updated-at type="dateTime">2026-04-15T16:34:56Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia nil="true"/>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C16856</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id nil="true"/>
  <biocyc-id nil="true"/>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB19186</drugbank-id>
  <pdb-id nil="true"/>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>NC(=O)OCC1NC(=N)N2CC(OS(O)(=O)=O)C(O)(O)C22NC(=N)NC12</moldb-smiles>
  <moldb-formula>C10H17N7O8S</moldb-formula>
  <moldb-inchi>InChI=1S/C10H17N7O8S/c11-6-15-5-3(2-24-8(13)18)14-7(12)17-1-4(25-26(21,22)23)10(19,20)9(5,17)16-6/h3-5,19-20H,1-2H2,(H2,12,14)(H2,13,18)(H3,11,15,16)(H,21,22,23)</moldb-inchi>
  <moldb-inchikey>ARSXTTJGWGCRRR-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">395.349</moldb-average-mass>
  <moldb-mono-mass type="decimal">395.085931245</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp nil="true"/>
  <hmdb-id>HMDB33507</hmdb-id>
  <chembl-id nil="true"/>
  <chemspider-id>9767779</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference nil="true"/>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM002999</chemdb-id>
  <dsstox-id>DTXSID90880095</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00004724</susdat-id>
  <iupac>{4-[(carbamoyloxy)methyl]-10,10-dihydroxy-2,6-diimino-decahydropyrrolo[1,2-c]purin-9-yl}oxidanesulfonic acid</iupac>
</compound>
